Morphologically-Directed Raman Spectroscopy

November 29th, 2023 | Technology

Subvisible particles (SVPs) are a significant quality attribute of injectable therapeutic proteins (TPs) that must be regulated due to potential medication product quality hazards. The existing compendial methods for analyzing SVPs for lot release give particle size and count information. On the other hand, chemical identification of specific particles is necessary for root-cause analysis. Researchers provide Morphologically-Directed Raman Spectroscopy (MDRS) for TP SVP characterization. For technique development, the following particles were used: (1) polystyrene microspheres, a traditional industry standard; (2) photolithographic (SU-8); and (3) ethylene tetrafluoroethylene (ETFE) particles, candidate reference materials created by NIST. In the study, MDRS created high-resolution images (> 90%) for ETFE particles spanning in size from 19 to 100 m, covering the majority of the SVP range, and produced morphological data equivalent to flow imaging microscopy. The method was used to analyze particles generated in stressed TPs, and Raman spectroscopy was used to identify individual particles chemically. MDRS may compare proteinaceous particles’ shape and transparency properties to those of reference materials. According to the findings, MDRS might be used to supplement the current TP’s SVP analysis system and product quality characterization workflow throughout the development and commercial lifecycle.

The work developed a new analytical approach for monitoring SVPs in TPs and characterizing proteinaceous particles in stressed mAb drug products using Morphologically-Directed Raman Spectroscopy. The purpose was to broaden TP SVP analysis methods for product quality characterization, which would influence public health. MDRS offered particle morphology and size distribution data comparable to FIM’s current orthogonal approach in analyzing monodisperse and polydisperse particles.

Read more

Related Content: Single Nanodiamond Sensors For In-Situ EPR Spectroscopy

Events & Shows

SPIE Defense + Commercial Sensing
23 Apr – 25 Apr, 2024
National Harbor, Maryland
Booth 938

SPIE Optifab 2024
17 Oct – 19 Oct, 2024
Rochester, New York
Booth 1303

The Equal Employment Opportunity Clause required under Executive Order 11246, and the employee notice clause pertaining to employee rights under the National Labor Relations Act, set forth in 29 CFR Part 471 Appendix A to Subpart A, are incorporated by reference in this purchase order. By accepting this purchase order, vendor additionally certifies that, to the extent applicable, this contractor and subcontractor shall abide by the requirements of 41 CFR §§ 60-1.4(a), 60-300.5(a) and 60-741.5(a). These regulations prohibit discrimination against qualified individuals based on their status as protected veterans or individuals with disabilities and prohibit discrimination against all individuals based on their race, color, religion, sex, sexual orientation, gender identity, or national origin. Moreover, these regulations require that covered prime contractors and subcontractors take affirmative action to employ and advance in employment individuals without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status or disability, that it complies with the authorities cited above, and that it does not maintain segregated facilities or permit its employees to perform services at locations where segregated facilities are maintained, as required by 41 CFR 60-1.8.